Jiangang Liu
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Neurofibromatosis and Schwannoma Cases, Neuroblastoma Research and Treatments, Meningioma and schwannoma management, Advanced Breast Cancer Therapies, Lung Cancer Research Studies
Most-Cited Works
- → Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes(2015)2,208 cited
- → Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma(2013)527 cited
- → Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer(2019)212 cited
- → Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma(2012)204 cited
- → Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer(2021)91 cited
- → miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities(2021)78 cited
- → Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients(2019)78 cited
- → Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study(2021)64 cited
- → A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer(2023)56 cited
- → Transcriptomic Analysis of Induced Pluripotent Stem Cells Derived from Patients with Bipolar Disorder from an Old Order Amish Pedigree(2015)46 cited